For therapeutic approaches employing CAR T cells as well as bispecific antibodies, it was observed that MSCs could protect MM cells from highly lytic BCMA-CAR T cells [150], whereas the lytic function of BCMA/CD3 bispecific antibodies was not that much influenced by MSCs [151]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.